The landscape of prostate cancer treatment has undergone a significant transformation over the past decade, driven by the landmark EMBARK trial (NCT02319837). This phase III global study has fundamentally altered the management of high-risk biochemically recurrent (BCR) prostate cancer, offering new hope to patients who previously faced limited options. In a recent podcast series, the principal investigators of the EMBARK trial, Dr. Steve Freedland of Cedars-Sinai Medical Center and Dr. Neal Shore of the START Cancer Research Center, provided a comprehensive analysis of the study’s findings and their application to real-world clinical practice.
Main Facts: The EMBARK Breakthrough
The EMBARK study investigated the efficacy of enzalutamide, a potent androgen receptor pathway inhibitor (ARPI), in patients with high-risk BCR prostate cancer—defined by a prostate-specific antigen (PSA) doubling time of nine months or less. The trial compared three arms: enzalutamide combined with leuprolide (an LHRH agonist), enzalutamide monotherapy, and leuprolide monotherapy.
The findings were unequivocal. Both the enzalutamide combination and enzalutamide monotherapy demonstrated a statistically significant improvement in metastasis-free survival (MFS) compared to leuprolide alone. Most impressively, the combination therapy showed a significant prolongation of overall survival. Critically, these benefits were achieved without introducing new safety signals, and health-related quality of life was preserved, as confirmed by robust patient-reported outcomes.
Chronology of the EMBARK Journey
The road to these practice-changing results spanned over a decade of rigorous clinical investigation.
- Trial Design and Enrollment: The study recruited a diverse cohort of patients who had undergone radical prostatectomy or radiation therapy as their primary treatment, ensuring the results were applicable across a broad spectrum of clinical backgrounds.
- Primary Endpoint Achievement: The trial successfully met its primary endpoint of metastasis-free survival, a result that served as the basis for subsequent FDA and EMA regulatory approvals.
- Plenary Presentations: The findings were showcased at major international forums, including the American Urological Association (AUA) and the European Society of Medical Oncology (ESMO), garnering widespread attention from the global oncology community.
- Long-Term Follow-up: As of 2025, the data have evolved to confirm not just radiographic progression benefits but a definitive survival advantage, cementing the role of enzalutamide in the treatment of high-risk BCR.
Supporting Data and Clinical Efficacy
A key takeaway from the EMBARK data is the consistency of efficacy regardless of the patient’s primary treatment. Dr. Shore noted that the trial population was evenly split: 25% had undergone radical prostatectomy, 25% had received radiation therapy, and 50% had received a combination of both. In every subset, the enzalutamide-based regimens outperformed standard androgen deprivation therapy (ADT).
The "off-treatment" protocol was another standout feature. Patients in the EMBARK trial were treated for 37-week cycles. If their PSA fell below 0.2 ng/mL, they entered a treatment suspension period. This protocol resulted in a median of 18 months off treatment for the combination arm, demonstrating that patients could maintain clinical benefits while enjoying extended periods free from the burden of daily medication.
Addressing Frequently Asked Questions: Expert Perspectives
In their discussion, Dr. Freedland and Dr. Shore addressed the most pressing questions raised by clinicians worldwide, providing clarity on the "art of medicine" in the post-EMBARK era.
1. The Question of Intermittent Therapy
While the EMBARK trial protocols featured one planned interruption, clinicians are now exploring whether multiple "holidays" from therapy are feasible. Dr. Freedland noted that while the trial didn’t explicitly test multiple cycles, patients who show a rapid and deep PSA nadir upon re-initiation are strong candidates for individualizing treatment schedules. "If it took years for the PSA to rise, I am much more comfortable with a second or third cycle," Freedland explained.
2. Delaying Systemic Therapy: A Dangerous Misconception
A common query involves the wisdom of waiting until metastatic castration-sensitive prostate cancer (mCSPC) develops before starting systemic therapy. Both experts vehemently discouraged this "wait-and-see" approach. Dr. Freedland likened it to treating a urinary tract infection: waiting until the patient develops sepsis is not a clinical strategy, but a failure of care. The data confirms that once a patient reaches the high-risk BCR threshold, early intervention with enzalutamide significantly reduces the risk of death by 40%.
3. The Role of PSMA-PET Imaging
The rise of PSMA-PET imaging has created a new dilemma: how to treat "conventional imaging-negative" (CIN) patients who appear positive on a PSMA-PET scan. Dr. Freedland advocates for an aggressive, multidisciplinary approach. "If I see a lesion, I want to radiate it, but I also want to use the systemic therapy that I know works," he stated. Combining metastasis-directed therapy (MDT) with systemic enzalutamide is becoming a preferred strategy for many, despite the lack of phase III data explicitly supporting this combination.
Implications for Clinical Practice
The EMBARK study has moved the needle from a "nihilistic" approach—where clinicians might delay treatment until symptomatic disease appeared—to a proactive, survival-focused strategy.
Shared Decision-Making
Individualization remains the cornerstone of modern prostate cancer care. For patients prioritized on maintaining sexual function and libido, enzalutamide monotherapy has emerged as a viable, well-tolerated alternative to combination therapy. For those who prioritize maximum survival benefit, the combination of enzalutamide and ADT is the gold standard.
Managing Side Effects
The experts emphasized that clinicians must be proactive in managing potential adverse events. For instance, breast-related tenderness—a known side effect of enzalutamide monotherapy—can be effectively mitigated through low-dose SERMs like tamoxifen or prophylactic radiation. This level of supportive care allows patients to remain on treatment longer and maintain a high quality of life.
Cardiovascular Health
Regarding cardiovascular concerns, Dr. Shore emphasized that while ARPIs do carry inherent risks, they are not insurmountable. The goal is to view the patient holistically, incorporating nutritional counseling, exercise, and cardiometabolic monitoring into the treatment plan, rather than relying solely on cardiovascular specialists who may not be readily available in every community setting.
Conclusion: The Future of High-Risk BCR Management
The EMBARK trial has provided an unprecedented level of evidence for the treatment of high-risk biochemically recurrent prostate cancer. By validating the efficacy of enzalutamide—both in combination and as monotherapy—the study has empowered clinicians to intervene earlier and more effectively.
Looking forward, the medical community anticipates further insights from real-world registries and prospective trials that will refine how we interpret PSMA-PET findings and integrate metastasis-directed therapies. However, for now, the message is clear: the era of waiting is over. With the tools provided by the EMBARK findings, physicians now have the ability to significantly alter the disease trajectory, prolong survival, and provide patients with the best possible outcomes in their journey against prostate cancer.
About the Author
